| Literature DB >> 26373465 |
Andrew M Tidball1, Jack M Parent1.
Abstract
Human induced pluripotent stem cell (iPSC) models of epilepsy are becoming a revolutionary platform for mechanistic studies and drug discovery. The skyrocketing pace of epilepsy gene discovery is vastly outstripping the development of in vivo animal models. Currently, antiepileptic drug prescribing to patients with specific genetic epilepsies is based on small-scale clinical trials and empiricism; however, rapid production of patient-derived iPSC models will allow for precision therapy. We review iPSC-based studies that have already afforded novel discoveries in diseases with epileptic phenotypes, as well as challenges to using iPSC-based neurological disease models. We also discuss iPSC-derived cardiomyocyte studies of arrhythmia-inducing ion channelopathies that exemplify novel drug discovery and use of multielectrode array technology that can be translated to epilepsy research. Beyond initial studies of Rett, Timothy, Phelan-McDermid, and Dravet syndromes, the stage is set for groundbreaking iPSC-based mechanistic and therapeutic discoveries in genetic epilepsies with the potential to impact patient treatment and quality of life. © AlphaMed Press.Entities:
Keywords: Channelopathies; Drug discovery; Epilepsy; Human induced pluripotent stem cells; Patient-specific modeling
Mesh:
Substances:
Year: 2015 PMID: 26373465 PMCID: PMC4958411 DOI: 10.1002/stem.2203
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277